Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide RNA-expression analysis after p53 activation in hepatocellular carcinoma

ABSTRACT: Genome-wide RNA-expression analysis after p53 activation in hepatocellular carcinoma

PROVIDER: PRJNA634530 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11831495_1.fastq.gz	Fastqsanger.gz
	SRR11831495_2.fastq.gz	Fastqsanger.gz
	SRR11831496_1.fastq.gz	Fastqsanger.gz
	SRR11831496_2.fastq.gz	Fastqsanger.gz
	SRR11831497_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Genome-wide microRNA-expression analysis after p53 activation in hepatocellular carcinoma

Project description:In order to characterize the differentially expressed miRNAs after the p53 activation , small RNA-seq were used after the overexpression of p53 in HepG2 cells. Four samples of HepG2 cells were subjected to small RNA-seq in two biological replicates.The HepG2 cells were treated with 1Âµg/ml doxorubicin for 24 hours to induce the expression of p53. The experimental group(dox-treated HepG2ï¼HepG2_24h_rep1 and HepG2_24h_rep2) and control group(untreated HepG2: HepG2_0h_rep1 and HepG2_0h_rep2) were subjected to small RNA-seq to identify the p53-regulated miRNAs.

2015-11-03 | E-GEOD-74588 | biostudies-arrayexpress

Genome-wide RNA-expression analysis after p53 activation in hepatocellular carcinoma

Project description:In order to characterize the differentially expressed mRNAs after the p53 activation ,RNA-seq were used after the overexpression of p53 in HepG2 cells.

2020-05-23 | GSE151061 | GEO

Genome-wide microRNA-expression analysis after p53 activation in hepatocellular carcinoma

Project description:In order to characterize the differentially expressed miRNAs after the p53 activation , small RNA-seq were used after the overexpression of p53 in HepG2 cells.

2015-11-03 | GSE74588 | GEO

p53-inducible long non-coding RNAs encode functional peptides in hepatocellular carcinoma cells [RNA-seq]

Project description:To identify p53-regulated lncRNAs responsive to DNA damage in human hepatocellular carcinoma (HCC) cells, we conducted paired-end and strand-specific RNA-seq using HepG2 wild-type and p53-knockout (HepG2-KO-p53) cells, which were devoid of p53 protein, using the CRISPR-Cas9 system treated with or without the DNA-damaging agent adriamycin (ADR)

2020-07-18 | GSE125756 | GEO

Fasting reverses drug-resistance in hepatocellular carcinoma through p53-dependent metabolic synergism

Project description:Cancer cells voraciously consume nutrients to support their growth, exposing a metabolic vulnerability that can be therapeutically exploited. Here we show in hepatocellular carcinoma (HCC) cells, xenografts, and in patient-derived HCC organoids that fasting can synergistically sensitise resistant HCC to sorafenib. Mechanistically, sorafenib acts non-canonically as inhibitor of mitochondrial respiration, causing resistant cells to depend on glycolysis for survival. Fasting, through reduction in glucose and impeded AKT/mTOR-signalling, prevents this Warburg shift. p53 is necessary and sufficient for the sorafenib-sensitizing effect of nutrient restriction and crucial for improvement of sorafenib efficacy through intermittent fasting (IF) in an orthotopic HCC mouse model. Together, our data indicate IF and sorafenib as clinically actionable, rational combination therapy for HCC with intact p53 signalling. As HCC therapy is currently severely limited by resistance, these results should instigate clinical studies with the goal of improving therapy response in advanced-stage, and possibly even early-stage, HCC.

2022-02-16 | PXD022723 | Pride

Genome-wide DNA methylation profiles of hepatocellular carcinoma

Project description:Genome-wide DNA methylation profiles of hepatocellular carcinoma

| PRJNA760921 | ENA

DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma

Project description:Genome-wide expression analysis of 228 hepatocellular carcinoma and 168 cirrhotic samples as part of a integrated study of gene expression and DNA-methylation de-regulation in patients with hepatocellular carcinoma Analysis of whole-genome transcriptome changes in human samples from hepatocellular carcinoma patients

2015-03-07 | GSE63898 | GEO

Reactivation of mutant p53 by SLMP53-2: a promising therapeutic option against hepatocellular carcinoma

Project description:In order to pursue the search for new reactivators of mutant p53, a small library of molecules was synthesized starting from a previously established lead (SLMP53-1). The molecules were tested in various cell-based assays and one, herein referred to as SLMP53-2, displayed a marked reduction of the IC50 values in NCI-H1299 cells expressing the p53 mutants (mutp53) R175H, Y220C, G245S, R248Q, R273C, and R273H. The activity of SLMP53-2 was then investigated using cancer cells lines expressing endogenous mutant p53 and focusing on hepatocellular carcinoma HuH-7 and breast ductal carcinoma HCC1419 cells endogenously expressing mutp53-Y220C. In HuH-7 cells, SLMP53-2 displayed a concentration-dependent growth inhibitory effect on colony formation, restored wt-like p53 protein conformation and transcriptional activity and displayed in vivo antitumour activity in a xenograft mouse model, with no apparent toxicity for normal tissues. To investigate more deeply the impact of SLMP53-2 treatments on gene expression in HuH-7 cells we performed microarray-based analysis using two different concentrations of the compound, corresponding to 2x and 3x IC50. We also employed the MDM2 inhibitor Nutlin alone or in combination with 2x IC50 SLMP53-2.

2020-04-13 | GSE124021 | GEO

Exome sequencing of lemur hepatocellular carcinoma

Project description:Exome sequencing of lemurs with hepatocellular carcinoma

2022-03-21 | PRJEB51774 | EVA

Expression profile of hepatocellular carcinoma-matrix interaction

Project description:Scirrous hepatocellular carcinoma is a rare type of liver tumor that is charecterized by fibrous stroma, biliary differentiation of tumor cells, and poorer prognosis. In this study, we aim to analyze the efefcts of collagen 1 on signal tranduction pathway activation, gene expression profile, and phenotypic changes of hepatocellular carcinoma.

2021-06-08 | GSE176270 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data